BR9509171A - Spray-dried microparticles as therapeutic vehicles - Google Patents

Spray-dried microparticles as therapeutic vehicles

Info

Publication number
BR9509171A
BR9509171A BR9509171A BR9509171A BR9509171A BR 9509171 A BR9509171 A BR 9509171A BR 9509171 A BR9509171 A BR 9509171A BR 9509171 A BR9509171 A BR 9509171A BR 9509171 A BR9509171 A BR 9509171A
Authority
BR
Brazil
Prior art keywords
spray
dried microparticles
therapeutic vehicles
therapeutic
vehicles
Prior art date
Application number
BR9509171A
Other languages
Portuguese (pt)
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of BR9509171A publication Critical patent/BR9509171A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9509171A 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles BR9509171A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94307126 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Publications (1)

Publication Number Publication Date
BR9509171A true BR9509171A (en) 1997-09-16

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509171A BR9509171A (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Country Status (16)

Country Link
EP (1) EP0783298A1 (en)
JP (1) JPH10506406A (en)
KR (1) KR970705979A (en)
AU (1) AU701440B2 (en)
BR (1) BR9509171A (en)
CA (1) CA2199954A1 (en)
CZ (1) CZ92497A3 (en)
FI (1) FI971332A0 (en)
HU (1) HUT77373A (en)
MX (1) MX9702357A (en)
NO (1) NO971438L (en)
NZ (1) NZ292980A (en)
PL (1) PL319600A1 (en)
RU (1) RU2147226C1 (en)
WO (1) WO1996009814A1 (en)
ZA (1) ZA958239B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
AU702955B2 (en) * 1996-05-17 1999-03-11 Quadrant Healthcare (Uk) Limited Microparticles and their use in wound therapy
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB9615435D0 (en) 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
US5961459A (en) * 1996-10-19 1999-10-05 Andaris Limited Use of hollow microcapsules in diagnosis and therapy
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
IL135126A0 (en) * 1997-09-29 2001-05-20 Inhale Therapeutic Syst Perforated microparticles and methods of use and preparation thereof
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
EP1056484A1 (en) * 1998-02-20 2000-12-06 Quadrant Healthcare (UK) Limited Products comprising fibrinogen for use in therapy
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
JP2002518432A (en) * 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド Large porous particles released from an inhaler
WO2000062819A1 (en) * 1999-04-21 2000-10-26 1355540 Ontario Inc. Formulations for detecting asthma
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
EP1239844B1 (en) 1999-12-20 2005-06-08 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
EP1351704B1 (en) * 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
CA2464656C (en) 2001-11-01 2013-07-16 Nektar Therapeutics Spray drying methods and compositions thereof
MXPA04005865A (en) 2001-12-19 2004-09-13 Nektar Therapeutics Pulmonary delivery of aminoglycosides.
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP5591434B2 (en) 2002-12-20 2014-09-17 ゼリス ファーマシューティカルズ インコーポレイテッド Intradermal injection method
KR20060015316A (en) * 2003-05-28 2006-02-16 넥타르 테라퓨틱스 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
MXPA06000720A (en) 2003-07-18 2006-08-23 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation.
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
CN103393601A (en) 2004-05-12 2013-11-20 巴克斯特国际公司 Microspheres comprising protein and showing injectability at high concentration of protein
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
UA90013C2 (en) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
EP2349219A4 (en) * 2008-09-29 2013-05-01 Univ Mercer Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (en) 2009-02-06 2010-08-11 ProFibrix BV Biodegradable extravascular support
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
JP5820807B2 (en) * 2009-05-28 2015-11-24 プロフィブリックス ビー．ヴイ． Fibrin sealant
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
BR112012016633A2 (en) 2010-01-08 2016-04-19 Profibrix Bv dry powder pharmaceutical composition and wound treatment method.
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
EP2635596B8 (en) 2010-11-01 2020-03-11 University of Technology Sydney Immune-modulating agents and uses therefor
BR112013023062B1 (en) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc STABLE SOLUTION FOR PARENTERAL INJECTION AND MANUFACTURING METHOD OF IT
EP3225235B1 (en) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
RU2013155713A (en) 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
KR102007057B1 (en) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. Formulations for the treatment of diabetes
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
BR112014032254B1 (en) 2012-06-26 2022-11-01 Ge Healthcare As PROCESS FOR THE PREPARATION OF A COMPOSITION, APPARATUS, AND USE OF AN APPLIANCE
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
EP2950797B1 (en) 2013-02-01 2019-09-11 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
MX2016004530A (en) 2013-10-08 2017-02-13 Lam Therapeutics Inc Rapamycin for the treatment of lymphangioleiomyomatosis.
PL3125875T3 (en) 2014-04-04 2023-11-20 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
DK3149049T3 (en) 2014-05-27 2023-01-23 Univ Queensland IL-22 FOR USE IN THE TREATMENT OF METABOLISM DISEASES
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
EP3209330B1 (en) 2014-10-07 2022-02-23 AI Therapeutics, Inc. An inhalable sirolimus formulation for the treatment of pulmonary hypertension
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016201248A1 (en) 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
WO2018075865A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions for the treatment of neurodegenerative diseases
CN110709061B (en) 2017-06-02 2023-09-08 Xeris药物公司 Anti-precipitation small molecule pharmaceutical formulations
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025193A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Pharmaceutical preparation for intra-airway administration
ES2177544T3 (en) * 1992-06-12 2002-12-16 Teijin Ltd ULTRAFININE POWDER TO INHALATE AND METHOD FOR PREPARATION.

Also Published As

Publication number Publication date
FI971332A (en) 1997-04-01
NO971438D0 (en) 1997-03-26
MX9702357A (en) 1997-06-28
RU2147226C1 (en) 2000-04-10
AU701440B2 (en) 1999-01-28
HUT77373A (en) 1998-03-30
JPH10506406A (en) 1998-06-23
KR970705979A (en) 1997-11-03
NZ292980A (en) 1999-02-25
EP0783298A1 (en) 1997-07-16
CA2199954A1 (en) 1996-04-04
CZ92497A3 (en) 1997-08-13
ZA958239B (en) 1996-09-30
FI971332A0 (en) 1997-04-01
AU3530295A (en) 1996-04-19
NO971438L (en) 1997-03-26
WO1996009814A1 (en) 1996-04-04
PL319600A1 (en) 1997-08-18

Similar Documents

Publication Publication Date Title
BR9509171A (en) Spray-dried microparticles as therapeutic vehicles
DE69816888D1 (en) vehicle body
PT1212327E (en) PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS
DE59812206D1 (en) Vehicle control-and-navigation methods
DE60034051D1 (en) ELECTRIC VEHICLE
GB9607035D0 (en) Spray-dried microparticles as therapeutic vehicles
ID23528A (en) THERAPEUTIC TREATMENT FOR SKIN DISORDERS
DE59806434D1 (en) Motor vehicle body part
GB9621825D0 (en) Microparticles and their use as therapeutic vehicles
ATA179896A (en) LOW-FIBRILLATION SHAPED BODY
DE69729782D1 (en) bus arbiter
TR200002729A3 (en) Vehicle armrest
KR970051627U (en) Car body front structure
KR970054487U (en) Vehicle body frame
KR970057624U (en) Car Bed
KR960004909U (en) Car body structure
KR970059563U (en) Car Stop Timer
KR970054495U (en) Car body structure
KR970054585U (en) Car body structure
KR950032997U (en) Agricultural Car
KR970051628U (en) Car body front structure
BR9602455A (en) Clinical functional stimulator
FI4254U1 (en) Vehicle body structure
SE9404074D0 (en) Collision protection activatable during travel
KR960021477U (en) Car tissue case

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal